Medifocus provides first Default Status Report



    TORONTO, Aug. 13 /CNW/ - Medifocus Inc. ("Medifocus" or the "Company")
(TSX: MFS) provides this bi-weekly Default Status Report in accordance with
National Policy 12-203 - Cease Trade Order for Continuous Disclosure Defaults
("NP 12-203"). On July 30, 2009, the Company announced that it was not able to
timely file its annual financial statements, accompanying management's
discussion and analysis and related CEO and CFO certifications (collectively,
the "2009 Annual Financial Statements") for the financial year ended March 31,
2009.
    In accordance with NP 12-203, and as previously announced, the Company
applied to the applicable securities commissions for Management Cease Trade
Orders related to the common shares of Medifocus to be imposed against certain
of the Company's executive officers (and at the discretion of the applicable
securities commissions, some or all of the directors, officers or insiders of
the Company) instead of a general Cease Trade Order being imposed against all
common shares of the Company. On August 7, 2009, the Ontario Securities
Commission issued a temporary management cease trade order expiring on August
22, 2009 related to the Company's common shares against certain officers of
the Company for so long as annual financial statements, certifications and
related MD&A are not filed. The issuance of such Management Cease Trade Orders
does not generally affect the ability of persons who have not been directors,
officers or insiders of the Company to trade the common shares of the Company.
A general Cease Trade Order may be imposed by the applicable securities
commissions if the Company fails to satisfy the provisions of the Alternative
Information Guidelines required pursuant to NP 12-203 (the "Alternative
Information Guidelines").
    The Company is working with its auditors to complete the audit of the
2009 Annual Financial Statements as soon as possible. Until the 2009 Annual
Financial Statements are filed, the Company intends to satisfy the Alternative
Information Guidelines by issuing bi-weekly Default Status Reports, each of
which will be issued in the form of a press release. If the 2009 Annual
Financial Statements are not filed beforehand, the Company intends to issue
its next Default Status Report on August 27, 2009.
    The Company reports that since its original announcement on July 30, 2009
(the "Notice") in respect of the delay in filing their 2009 Annual Financial
Statements, there have not been any material changes to the information
provided in the Notice other than as described herein nor any failure by the
Company in fulfilling its stated intention with respect to satisfying the
Alternative Information Guidelines. In addition, there has not been any other
specified default by the Company under NP 12-203, nor are any anticipated and
there is no other material information concerning the affairs of the Company
that has not been generally disclosed.

    
    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.
    

    Medifocus owns a patented microwave focusing technology platform (the
Adaptive Phased Array ("APA") technology), which can precisely target and
control microwave energy to cause heating in cancerous tumors anywhere in the
body reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures,
to treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger
the targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the
Massachusetts Institute of Technology, Medifocus has further refined the
precision of the microwave focusing and control ability and developed a
commercial system dedicated exclusively for the treatment of Breast Cancer.
Please visit www.medifocusinc.com for more details.





For further information:

For further information: Gilbert Chan, NAI Interactive Ltd.,
gil@na-investor.com, (604) 488-8878, 1-866-833-5517; Dr. Augustine Cheung,
Medifocus Inc., acheung@medifocusinc.com, Telephone (410) 290-5734

Organization Profile

MEDIFOCUS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890